David R. Sibley

26.1k total citations · 9 hit papers
263 papers, 20.0k citations indexed

About

David R. Sibley is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cell Biology. According to data from OpenAlex, David R. Sibley has authored 263 papers receiving a total of 20.0k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Molecular Biology, 167 papers in Cellular and Molecular Neuroscience and 16 papers in Cell Biology. Recurrent topics in David R. Sibley's work include Receptor Mechanisms and Signaling (191 papers), Neurotransmitter Receptor Influence on Behavior (119 papers) and Neuroscience and Neuropharmacology Research (56 papers). David R. Sibley is often cited by papers focused on Receptor Mechanisms and Signaling (191 papers), Neurotransmitter Receptor Influence on Behavior (119 papers) and Neuroscience and Neuropharmacology Research (56 papers). David R. Sibley collaborates with scholars based in United States, Australia and Sweden. David R. Sibley's co-authors include Frederick J. Monsma, Robert J. Lefkowitz, Ian Creese, Charles R. Gerfen, Lawrence C. Mahan, Thomas N. Chase, Marc G. Caron, Thomas M. Engber, Zvi Susel and Mark W. Hamblin and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David R. Sibley

253 papers receiving 19.4k citations

Hit Papers

D 1 and D 2 Dopamine Rece... 1985 2026 1998 2012 1990 1992 2003 1985 1987 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
    1990 2.4k citations Frederick J. Monsma, David R. Sibley et al. profile →
  2. Molecular biology of dopamine receptors
    1992 846 citations David R. Sibley, Frederick J. Monsma Trends in Pharmacological Sciences profile →
  3. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
    2003 771 citations David R. Sibley et al. profile →
  4. Molecular mechanisms of receptor desensitization using the β-adrenergic receptor-coupled adenylate cyclase system as a model
    1985 633 citations David R. Sibley et al. profile →
  5. Regulation of transmembrane signaling by receptor phosphorylation
    1987 579 citations David R. Sibley et al. profile →
  6. Geographies of Exclusion
    1996 534 citations David R. Sibley et al. profile →
  7. Multiple D2 dopamine receptors produced by alternative RNA splicing
    1989 524 citations Frederick J. Monsma, David R. Sibley et al. profile →
  8. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
    1993 512 citations Frederick J. Monsma, David R. Sibley et al. profile →
  9. Cross-talk between cellular signalling pathways suggested by phorbol-ester-induced adenylate cyclase phosphorylation
    1987 457 citations David R. Sibley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David R. Sibley United States 69 12.7k 11.9k 1.9k 1.6k 1.5k 263 20.0k
Peter R. Schofield Australia 74 8.3k 0.7× 9.8k 0.8× 1.2k 0.6× 1.8k 1.1× 1.7k 1.2× 343 20.6k
Olivier Civelli United States 67 13.0k 1.0× 11.1k 0.9× 961 0.5× 2.1k 1.2× 1.8k 1.2× 202 20.3k
Randy Blakely United States 86 11.6k 0.9× 10.7k 0.9× 1.1k 0.5× 2.3k 1.4× 1.9k 1.3× 326 22.7k
David K. Grandy United States 67 11.6k 0.9× 9.8k 0.8× 957 0.5× 1.4k 0.9× 1.3k 0.9× 174 16.9k
Jacques Mallet France 73 7.2k 0.6× 9.6k 0.8× 1.5k 0.8× 1.3k 0.8× 1.1k 0.8× 367 18.7k
Susan Amara United States 63 15.0k 1.2× 11.1k 0.9× 799 0.4× 897 0.5× 1.3k 0.9× 165 20.2k
Daniël Hoyer Switzerland 83 13.3k 1.1× 13.9k 1.2× 1.2k 0.6× 2.3k 1.4× 1.8k 1.2× 371 26.6k
Luigi F. Agnati Italy 67 10.1k 0.8× 9.7k 0.8× 1.4k 0.7× 1.6k 0.9× 515 0.3× 342 17.0k
Raul R. Gainetdinov Russia 79 17.8k 1.4× 15.1k 1.3× 2.6k 1.3× 3.4k 2.0× 2.8k 1.9× 333 28.2k
Michael J. Zigmond United States 68 9.5k 0.7× 8.2k 0.7× 4.9k 2.5× 2.1k 1.3× 1.1k 0.7× 206 20.7k

Countries citing papers authored by David R. Sibley

Since Specialization
Citations

This map shows the geographic impact of David R. Sibley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Sibley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Sibley more than expected).

Fields of papers citing papers by David R. Sibley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Sibley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Sibley. The network helps show where David R. Sibley may publish in the future.

Co-authorship network of co-authors of David R. Sibley

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Sibley. A scholar is included among the top collaborators of David R. Sibley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Sibley. David R. Sibley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sibley, David R.. (2024). The Enduring Impact of Pharmacological Reviews–Editorial. Pharmacological Reviews. 76(5). 620–621.
2.
Flores, Rodolfo J., Snehashis Roy, Ted B. Usdin, et al.. (2024). Dissociable control of motivation and reinforcement by distinct ventral striatal dopamine receptors. Nature Neuroscience. 28(1). 105–121. 5 indexed citations
3.
Sánchez‐Soto, Marta, et al.. (2023). GRK2 Enhances ß-arrestin Recruitment to the D2 Dopamine Receptor Through a Mechanism that is Independent From Receptor Phosphorylation or G Protein Activation. Journal of Pharmacology and Experimental Therapeutics. 385. 148–148. 1 indexed citations
4.
Sibley, David R., Ashley N. Nilson, Amy E. Moritz, & Lei Shi. (2023). Dopamine receptor divergence revealed using a common ligand. Trends in Pharmacological Sciences. 44(10). 637–639.
5.
Sánchez‐Soto, Marta, Amy E. Moritz, Julia Drube, et al.. (2023). G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D2 Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation. Biomolecules. 13(10). 1552–1552. 6 indexed citations
6.
Moritz, Amy E., et al.. (2023). Delineation of G Protein-Coupled Receptor Kinase Phosphorylation Sites within the D1 Dopamine Receptor and Their Roles in Modulating β-Arrestin Binding and Activation. International Journal of Molecular Sciences. 24(7). 6599–6599. 5 indexed citations
7.
Aslanoglou, Despoina, Suzanne Bertera, Laura Friggeri, et al.. (2022). Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine. iScience. 25(8). 104771–104771. 12 indexed citations
8.
Free, R. Benjamin, Ashley N. Nilson, Trevor Doyle, et al.. (2022). Identification and Characterization of ML321: A Novel and Highly Selective D 2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity. ACS Pharmacology & Translational Science. 6(1). 151–170. 1 indexed citations
9.
Aslanoglou, Despoina, Suzanne Bertera, Marta Sánchez‐Soto, et al.. (2021). Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry. 11(1). 59–59. 68 indexed citations
10.
Keck, Thomas M., R. Benjamin Free, Alessandro Bonifazi, et al.. (2019). Dopamine D4 Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry. 62(7). 3722–3740. 22 indexed citations
11.
Verma, Ravi Kumar, Ara M. Abramyan, Mayako Michino, et al.. (2018). The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology. 14(1). e1005948–e1005948. 20 indexed citations
12.
Maison, Stéphane F., et al.. (2012). Dopaminergic Signaling in the Cochlea: Receptor Expression Patterns and Deletion Phenotypes. Journal of Neuroscience. 32(1). 344–355. 71 indexed citations
13.
Skinbjerg, Mette, Yoon Namkung, Christer Halldin, Robert B. Innis, & David R. Sibley. (2009). Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2and D3dopamine receptors. Synapse. 63(6). 462–475. 29 indexed citations
14.
Argilli, Emanuela, David R. Sibley, Robert C. Malenka, Pamela M. England, & Antonello Bonci. (2008). Mechanism and Time Course of Cocaine-Induced Long-Term Potentiation in the Ventral Tegmental Area. Journal of Neuroscience. 28(37). 9092–9100. 196 indexed citations
15.
Bek, Martin J., Laureano D. Asico, Gilbert M. Eisner, David R. Sibley, & Pedro A. José. (2000). Non-N-Methyl D-Aspartate Receptors Are Involved in the Hypertension of D5 Dopamine Receptor Knockout Mice.. Hypertension. 36. 726–726. 2 indexed citations
16.
Sleight, Andrew J., Frank Boess, Anne Bourson, David R. Sibley, & Frederick J. Monsma. (1997). 5-HT 6 and 5-HT 7 Receptors: Molecular Biology, Functional Correlates and Possible Therapeutic Indications.. Drug News & Perspectives. 10(4). 214–224. 12 indexed citations
17.
Chronwall, Bibie M., et al.. (1996). Melanotrope dopamine D2 receptor isoform expression in the developing rat pituitary. International Journal of Developmental Neuroscience. 14(2). 77–86. 13 indexed citations
18.
Albrecht, Frederick E., John Drago, Robin A. Felder, et al.. (1996). Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension.. Journal of Clinical Investigation. 97(10). 2283–2288. 154 indexed citations
19.
Sibley, David R. & Miles D. Houslay. (1994). Regulation of cellular signal transduction pathways by densensitization and amplification. Wiley eBooks.
20.
Sibley, David R. & Frederick J. Monsma. (1992). Molecular biology of dopamine receptors. Trends in Pharmacological Sciences. 13(2). 61–69. 846 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter R. Schofield Breakdown of academic impact, for papers by Olivier Civelli Breakdown of academic impact, for papers by Randy Blakely Breakdown of academic impact, for papers by David K. Grandy Breakdown of academic impact, for papers by Jacques Mallet Breakdown of academic impact, for papers by Susan Amara Breakdown of academic impact, for papers by Daniël Hoyer Breakdown of academic impact, for papers by Luigi F. Agnati Breakdown of academic impact, for papers by Raul R. Gainetdinov Breakdown of academic impact, for papers by Michael J. Zigmond
Rankless by CCL
2026